Unfit patients even have the choice of venetoclax as well as obinutuzumab (VO) as frontline therapy. This relies over a period III demo that compared VO with ClbO in elderly/unfit individuals.113 VO was remarkable when it comes to response charge and progression-cost-free survival, and experienced a